Delivery Order SPE2DB22D2206-SPE2DB25FKD31
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 24, 2025, for the supply of RINVOQ ER 30 mg tablets in quantities of 30s, with a contract ceiling value of $24,269.37. This is a firm fixed price delivery order with an ultimate completion date of October 27, 2025, and represents a non-competitive set-aside award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units) valued at $17,437.44. This firm fixed-price delivery order, which is expected to be completed by September 10, 2025, represents a non-set-aside competitive procurement. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company serves as a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) with a ceiling value of $6,558.40. Issued on November 14, 2025, with an ultimate completion date of November 17, 2025, this firm fixed-price delivery order represents a competitively awarded, non-set-aside procurement. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets in a quantity of 30 units, with a ceiling value of $87,792.14. This firm fixed-price delivery order, awarded on July 23, 2025, represents a non-set-aside competitive award with an ultimate completion date of July 24, 2025. The pharmaceutical products will be delivered to the company's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office and...
- The Defense Logistics Agency awarded a $26,705.50 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) with a firm fixed price structure. This non-competitive delivery order was awarded on September 10, 2025, with an ultimate completion date of September 11, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 28, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units) with a ceiling value of $40,502.39. This firm fixed-price delivery order, with an ultimate completion date of October 29, 2025, represents a non-competitive, non-set-aside award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary...
- The Defense Logistics Agency awarded a delivery order valued at $9,334.98 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose packages) on October 27, 2025, with completion targeted for October 28, 2025. This is a firm fixed price delivery order with no set-aside designation, issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract number SPE2DX). The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of RINVOQ ER 15 mg tablets (30-unit packages) valued at $34,723.92. This is a firm fixed-price delivery order with an ultimate completion date of September 25, 2025, and represents a competitive award with no set-aside designation. The order will be fulfilled at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $18,061.85 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on November 5, 2025, with completion expected by November 6, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion vehicle running through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units) with a ceiling value of $19,206.25. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award, and is expected to be completed by July 15, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FKD31Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of RINVOQ ER 15 mg tablets in a quantity of 30 units, with a ceiling value of $6,888.58. This is a firm fixed-price delivery order with an ultimate completion date of September 29, 2025, and carries no set-aside designation, indicating it was competitively awarded. The place of performance is listed as Conshohocken, Pennsylvania, which is also the location of AmerisourceBergen's corporate headquarters. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply vehicle valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor serving federal medical procurement needs, AmerisourceBergen supplies a broad range of medications and medical products to support military and veteran healthcare systems. RINVOQ (upadacitinib) is a prescription medication used to treat rheumatoid arthritis and other inflammatory conditions, reflecting the company's portfolio of specialized therapeutic pharmaceuticals for Department of Defense healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.9k | 9/26/25 |